Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma
- Authors
- Hong, Junshik; Kim, Ji Yeon; Ahn, Hee Kyung; Lee, Sang-Min; Sym, Sun Jin; Park, Jinny; Cho, Eun Kyung; Ahn, Jeong Yeal; Park, Sanghui; Lee, Sang Pyo; Shin, Dong Bok; Lee, Jae Hoon
- Issue Date
- Apr-2013
- Publisher
- Springer Verlag
- Keywords
- Rituximab; Non-Hodgkin lymphoma; Infusion-related reaction; Bone marrow involvement
- Citation
- Supportive Care in Cancer, v.21, no.4, pp 1145 - 1152
- Pages
- 8
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Supportive Care in Cancer
- Volume
- 21
- Number
- 4
- Start Page
- 1145
- End Page
- 1152
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/65342
- DOI
- 10.1007/s00520-012-1639-9
- ISSN
- 0941-4355
1433-7339
- Abstract
- The purpose of this study is to evaluate risk factors for infusion-related reaction (IRR) following rituximab administration in patients with B cell non-Hodgkin lymphoma. A retrospective analysis was conducted of patients with newly diagnosed B cell lymphoma who have received rituximab-included immunochemotherapy with appropriate premedication and commonly used schedule of infusion rate. IRRs were graded by review of the patients' electronic medical record according to the Common Terminology Criteria for Adverse Events version 4.0. One hundred and sixty-nine patients were included in the analysis and most of the patients (150; 88.8 %) had diffuse large B cell lymphoma (DLBCL). Thirty-six patients (21.3 %) had any grade of IRRs: 23 patients were grade (G) 1 (13.6 %), 13 had a parts per thousand yenG2 IRRs (7.7 %), and only 4 had a parts per thousand yenG3 IRRs (2.4 %). All except one patient had IRR during the first cycle and only two had repetitive IRR thereafter. Bone marrow (BM) involvement was the strongest risk factor for IRR in multivariable analysis (odds ratio 4.06, 95 % confidence interval 1.67-9.89; p = 0.002). A subgroup analysis confined to patients with DLBCL showed very similar results when compared with the entire population, and patients with DLBCL who had a parts per thousand yenG2 IRR showed shorter event-free and overall survival when compared to those who did not. BM involvement is predictive of occurrence of IRR during rituximab administration in patients with B cell lymphoma. More intensive premedication and careful observation for IRR during rituximab administration are required for patients with B cell lymphoma who have BM involvement.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 5. Others > ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.